Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in Detroit, Michigan

This page shows live ClinicalTrials.gov search results for Detroit, Michigan, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 5:39 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1670
Shown on this page
12
Current sort
Recently updated
Location scope
Detroit, MI
Filters apply within this location only.

The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.

Filter and sort this location

These controls apply only within Detroit, Michigan. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 709–720 of 1,670 matching trials in Detroit, MI.
Indexed local directory records.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Stored official records

Open in full search
Recruiting Phase 1Phase 2 Interventional

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

NCT04585750
View directory record Official record
Conditions
Advanced Malignant Neoplasm, Advanced Solid Tumor, Breast Cancer, Colorectal Cancer, ER/PR Positive Breast Cancer, ER/PR(+), Her2(-) Breast Cancer, Endometrial Cancer, Gall Bladder Cancer, HER2+ Breast Cancer, HER2- Breast Cancer, HER2-negative Breast Cancer, HER2-positive Breast Cancer, Head and Neck Cancer, Locally Advanced, Lung Cancer, Metastatic Cancer, Metastatic Solid Tumor, NSCLC, NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Other Cancer, Ovarian Cancer, Prostate Cancer, SCLC, Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Small Cell Lung Carcinoma, TNBC, Triple Negative Breast Cancer
Interventions
pembrolizumab, rezatapopt
Drug
Lead sponsor
PMV Pharmaceuticals, Inc
Industry
Eligibility
12 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
32
States / cities
Irvine, California • La Jolla, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 13, 2026, 9:33 PM EDT
Active, not recruiting Phase 3 Interventional

Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery

NCT03180268
View directory record Official record
Conditions
Grade 2 Meningioma, Intracranial Meningioma
Interventions
Biospecimen Collection, Clinical Observation, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Proton Beam Radiation Therapy, Quality-of-Life Assessment
Procedure · Other · Radiation
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2032
U.S. locations
198
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 162 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Nov 5, 2026, 3:13 AM EST
Recruiting Phase 3 Interventional

CAR-T Long Term Follow Up (LTFU) Study

NCT02445222
View directory record Official record
Conditions
Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program
Interventions
Previously treated CAR-T patients
Genetic
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
0 Years to 100 Years
Enrollment
1,105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2039
U.S. locations
42
States / cities
Phoenix, Arizona • Duarte, California • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Nov 4, 2026, 7:36 PM EST
Recruiting No phase listed Observational Accepts healthy volunteers

Observational Study of Decentralized Urine Optical Interaction Patterns Associated With Environmental Microplastic and Nanoplastic Exposure

NCT07775495
View directory record Official record
Conditions
Healthy Adult Participants
Interventions
Not listed
Lead sponsor
Ecotera Health LLC
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
51
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 13, 2026, 8:35 PM EDT
Recruiting Phase 2 Interventional

RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures

NCT06798896
View directory record Official record
Conditions
Focal Onset Seizures
Interventions
Placebo, SPN-817
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
39
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 14, 2026, 12:13 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

NCT06362252
View directory record Official record
Conditions
Extensive Stage-small Cell Lung Cancer
Interventions
Atezolizumab, Carboplatin, Ifinatamab deruxtecan
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
26
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 5, 2026, 8:11 PM EDT
Terminated Phase 3 Interventional

A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation

NCT05636176
View directory record Official record
Conditions
Heart Failure
Interventions
Placebo, Ziltivekimab
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
4,874 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
172
States / cities
Alexander City, Alabama • Fairhope, Alabama • Huntsville, Alabama + 141 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Nov 6, 2026, 5:39 AM EST
Recruiting Phase 1 Interventional

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

NCT05176483
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma (ccRCC), Colorectal Cancer (CRC), Drug-Drug Interaction (DDI), Head and Neck Squamous Cell Carcinoma (HNSCC), Hepatocellular Carcinoma (HCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Non-Clear Cell Renal Cell Carcinoma (nccRCC), Non-small Cell Lung Cancer (NSCLC), Renal Cell Carcinoma (RCC), Solid Tumor, Urothelial Carcinoma (UC)
Interventions
DDI Probe Cocktail, Docetaxel, Ipilimumab, Nivolumab, Nivolumab + Relatlimab, Prednisone, Zanzalintinib
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
1,394 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
46
States / cities
Phoenix, Arizona • Tucson, Arizona • Palo Alto, California + 38 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 28, 2026, 3:37 AM EDT
Active, not recruiting Phase 3 Interventional

A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy

NCT04629248
View directory record Official record
Conditions
Primary Membranous Nephropathy
Interventions
Acetaminophen, Diphenhydramine, Methylprednisolone, Obinutuzumab, Tacrolimus
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
8
States / cities
San Francisco, California • Aurora, Colorado • Altamonte Springs, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 15, 2026, 6:19 AM EDT
Active, not recruiting Not applicable Interventional Results available

da Vinci SP® Investigational Device Exemption Study in Colorectal Procedures

NCT04403022
View directory record Official record
Conditions
Benign or Malignant Rectal or Colon Tumors, Colorectal Cancer
Interventions
Robotic Assisted Surgery
Device
Lead sponsor
Intuitive Surgical
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
7
States / cities
Orlando, Florida • Detroit, Michigan • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Nov 1, 2026, 10:47 AM EST
Active, not recruiting Phase 2 Interventional Results available

Radiation Therapy With or Without Apalutamide in Treating Patients With Recurrent Prostate Cancer, the BALANCE Trial

NCT03371719
View directory record Official record
Conditions
Recurrent Prostate Carcinoma, Stage III Prostate Adenocarcinoma AJCC v7, Stage IV Prostate Adenocarcinoma AJCC v7
Interventions
Apalutamide, External Beam Radiation Therapy, Placebo Administration
Drug · Radiation · Other
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
352
States / cities
Gilbert, Arizona • Peoria, Arizona • Scottsdale, Arizona + 251 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Nov 6, 2026, 1:14 AM EST
Active, not recruiting Phase 1 Interventional

Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

NCT03170960
View directory record Official record
Conditions
Castration-resistant Prostate Cancer, Colorectal Cancer, Differentiated Thyroid Cancer, Endometrial Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Head and Neck Cancer, Hepatocellular Carcinoma, Lower Esophageal Cancer, Non-Small Cell Lung Cancer, Ovarian Cancer, Renal Cell Carcinoma, Triple Negative Breast Cancer, Urothelial Carcinoma
Interventions
atezolizumab, cabozantinib
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
914 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
57
States / cities
Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 45 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 13, 2026, 4:02 PM EDT